Abstract
Aberrant DNA methylation at the 5-position of cytosine, catalyzed by DNA methyltransferases (DNMTs), is associated with not only various cancers by silencing of tumor suppressor genes but also other diseases. The DNMTs, especially the DNMT1, DNMT3A and DNMT3B, are often overexpressed in various cancer tissues and cell lines. DNMTs are important epigenetic targets for drug development since the DNA methylation is reversible. This review summarizes an array of nucleoside and non-nucleoside inhibitors of DNMTs, as well as their biological activities. Among these inhibitors, the nucleoside analogue azacytidine and its deoxy derivative decitabine are both irreversible DNMT inhibitors and approved for the treatment of myelodysplastic syndrome.
Keywords: Epigenetic, DNA methylation, Inhibitor, Selectivity, Nucleoside, Cancer.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:DNA Methyltransferase Inhibitors and their Therapeutic Potential
Volume: 18 Issue: 28
Author(s): Zehao Zhou, Huan-Qiu Li*Feng Liu*
Affiliation:
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou, Jiangsu 215123,China
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou, Jiangsu 215123,China
Keywords: Epigenetic, DNA methylation, Inhibitor, Selectivity, Nucleoside, Cancer.
Abstract: Aberrant DNA methylation at the 5-position of cytosine, catalyzed by DNA methyltransferases (DNMTs), is associated with not only various cancers by silencing of tumor suppressor genes but also other diseases. The DNMTs, especially the DNMT1, DNMT3A and DNMT3B, are often overexpressed in various cancer tissues and cell lines. DNMTs are important epigenetic targets for drug development since the DNA methylation is reversible. This review summarizes an array of nucleoside and non-nucleoside inhibitors of DNMTs, as well as their biological activities. Among these inhibitors, the nucleoside analogue azacytidine and its deoxy derivative decitabine are both irreversible DNMT inhibitors and approved for the treatment of myelodysplastic syndrome.
Export Options
About this article
Cite this article as:
Zhou Zehao , Li Huan-Qiu*, Liu Feng*, DNA Methyltransferase Inhibitors and their Therapeutic Potential, Current Topics in Medicinal Chemistry 2018; 18 (28) . https://dx.doi.org/10.2174/1568026619666181120150122
DOI https://dx.doi.org/10.2174/1568026619666181120150122 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis
Current Genomics TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma
Current Cancer Drug Targets Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology Therapeutic Antibodies
Current Molecular Medicine T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
Current Clinical Pharmacology Prostate Cancer Immunotherapy: An Evolving Field
Current Cancer Therapy Reviews Advances in Nanomaterials for Diagnosis and Therapy of Leukemia
Recent Patents on Nanomedicine Mechanisms of Drug-Induced Mitotic Catastrophe in Cancer Cells
Current Pharmaceutical Design Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry On the Role of Endothelial TRPC3 Channels in Endothelial Dysfunction and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Dendritic Cell Immunotherapy for Malignant Gliomas
Reviews on Recent Clinical Trials Preface
Current Pharmaceutical Design Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry Proteomic Analysis of Liver Preservation Solutions Prior to Liver Transplantation
Current Proteomics Snake Venom Induced Local Toxicities: Plant Secondary Metabolites as an Auxiliary Therapy
Mini-Reviews in Medicinal Chemistry New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Current Drug Targets Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets